Tech Company Financing Transactions
Marvel Biosciences Funding Round
National Research Council of Canada participated in a funding round for Marvel Biosciences. The funding round closed on 2/18/2026.
Transaction Overview
Company Name
Announced On
2/18/2026
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
This support will allow us to directly address a clinical barrier faced by patients and caregivers and prepare MB-204 dosing to be aligned with future pediatric clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
505 8th Avenue S.W. 420
Calgary, Alberta, T2P 1G2
Canada
Calgary, Alberta, T2P 1G2
Canada
Phone
Website
Email Address
Overview
Marvel Biosciences is a Canadian biotechnology company developing breakthrough therapies for complex neurological and neurodevelopmental disorders, including autism spectrum disorder, Rett syndrome, and Fragile X syndrome. We are developing transformative treatments for patients with neurological and neurodevelopmental disorders through breakthrough science built on proven research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
J. Roderick Matheson
Chief Financial Officer
Harry Nijjar
President
Mark Williams
Browse more venture capital transactions:
Prev: 2/18/2026: Nihin Media venture capital transaction
Next: 2/18/2026: ProSomnus Sleep Technologies venture capital transaction
Share this article
News on VC Transactions
We report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs